108 related articles for article (PubMed ID: 9114904)
1. A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril.
Macdonald NJ; Elliott HL; Hughes DM; Reid JL
Br J Clin Pharmacol; 1993 Sep; 36(3):201-4. PubMed ID: 9114904
[TBL] [Abstract][Full Text] [Related]
2. The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril.
Macdonald NJ; Sioufi A; Howie CA; Wade JR; Elliott HL
Br J Clin Pharmacol; 1993 Sep; 36(3):205-9. PubMed ID: 9114905
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
King JN; Mauron C; Kaiser G
Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of benazepril in hypertensive patients with normal and impaired renal function.
Shionoiri H; Ueda S; Minamisawa K; Minamisawa M; Takasaki I; Sugimoto K; Gotoh E; Ishii M
J Cardiovasc Pharmacol; 1992 Sep; 20(3):348-57. PubMed ID: 1279278
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly.
Kaiser G; Ackermann R; Dieterle W; Durnin CJ; McEwen J; Ghose K; Richens A; Holmes IB
Eur J Clin Pharmacol; 1990; 38(4):379-85. PubMed ID: 2344861
[TBL] [Abstract][Full Text] [Related]
6. Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril.HCl.
King JN; Humbert-Droz E; Maurer M
J Vet Pharmacol Ther; 1999 Dec; 22(6):360-7. PubMed ID: 10651464
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog.
King JN; Maurer M; Morrison CA; Mauron C; Kaiser G
Xenobiotica; 1997 Aug; 27(8):819-29. PubMed ID: 9293618
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of benazepril hydrochloride in patients with major proteinuria.
Schweizer C; Kaiser G; Dieterle W; Mann J
Eur J Clin Pharmacol; 1993; 44(5):463-6. PubMed ID: 8359184
[TBL] [Abstract][Full Text] [Related]
9. Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril.
Elliott HL; Macdonald NJ; Meredith PA; Reid JL
Clin Pharmacol Ther; 1992 Mar; 51(3):260-5. PubMed ID: 1312002
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.
King JN; Maurer M; Toutain PL
J Vet Pharmacol Ther; 2003 Jun; 26(3):213-24. PubMed ID: 12755906
[TBL] [Abstract][Full Text] [Related]
11. Effects of prolonged administration of the angiotensin converting enzyme inhibitor CGS 16617 in normotensive volunteers.
Waeber G; Burnier M; Porchet M; Nussberger J; Waeber B; Brunner HR
Eur J Clin Pharmacol; 1989; 36(6):587-91. PubMed ID: 2550244
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence of a new liquid formulation of benazepril compared with the reference tablet product.
Kelers K; Devi JL; Anderson GA; Zahra P; Vine JH; Whittem T
Aust Vet J; 2013 Aug; 91(8):312-9. PubMed ID: 23889096
[TBL] [Abstract][Full Text] [Related]
13. Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
Cawello W; Boekens H; Waitzinger J; Miller U
Int J Clin Pharmacol Ther; 2002 Jan; 40(1):9-17. PubMed ID: 11837383
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of the blood pressure response to exogenous angiotensin I after oral administration of benazepril to healthy adult horses.
Afonso T; Giguère S; Rapoport G; Brown SA; Coleman AE
Equine Vet J; 2017 May; 49(3):358-362. PubMed ID: 27224673
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses.
Serrano-Rodríguez JM; Gómez-Díez M; Esgueva M; Castejón-Riber C; Mena-Bravo A; Priego-Capote F; Serrano Caballero JM; Muñoz A
Vet J; 2016 Feb; 208():38-43. PubMed ID: 26639833
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of benazepril relative to other ACE inhibitors.
Gengo FM; Brady E
Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV44-50; discussion IV51-5. PubMed ID: 1893642
[TBL] [Abstract][Full Text] [Related]
17. Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats.
King JN; Strehlau G; Wernsing J; Brown SA
J Vet Pharmacol Ther; 2002 Oct; 25(5):371-8. PubMed ID: 12423228
[TBL] [Abstract][Full Text] [Related]
18. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment.
Lees KR; Reid JL
Clin Pharmacol Ther; 1987 Jun; 41(6):597-602. PubMed ID: 3034468
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.
Mochel JP; Fink M; Peyrou M; Soubret A; Giraudel JM; Danhof M
Pharm Res; 2015 Jun; 32(6):1931-46. PubMed ID: 25446774
[TBL] [Abstract][Full Text] [Related]
20. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure.
Balfour JA; Goa KL
Drugs; 1991 Sep; 42(3):511-39. PubMed ID: 1720384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
